Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [6] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [9]

2 days ago · **Dr. McLaughlin is a member of the adult sotatercept steering committee, an investigator in the ZENITH and HYPERION trials and a paid consultant to Merck. About HYPERION The HYPERION study ( NCT04811092 ) is a global, double-blind, placebo-controlled clinical trial to evaluate WINREVAIR when added to background PAH therapy in newly …

Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the growth-promoting and growth-inhibiting signalling pathways.

2 days ago · Merck Winrevair pulmonary arterial hypertension sotatercept. Merck has halted the phase 3 HYPERION trial of its pulmonary arterial hypertension (PAH) treatment Winrevair after reviewing positive ...

2 days ago · RAHWAY, N.J., January 30, 2025--Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Dec 28, 2024 · The Food and Drug Administration and European Medicines Agency have approved Sotatercept, offering a promising new therapeutic option. Sotatercept is a fusion protein composed of the activin receptor fused to the human IgGE, initially designed to trap TGF-β ligands with high affinity for activins.

Mar 6, 2023 · Sotatercept is a fusion protein that traps activins and growth differentiation factors involved in pulmonary arterial hypertension.

Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.

Apr 16, 2024 · Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered subcutaneously (under the skin) and may be used to treat adults with pulmonary arterial hypertension (PAH, WHO Group 1).

Mar 31, 2021 · Sotatercept is a first-in-class therapeutic fusion protein that targets an imbalance in activin–growth differentiation factor and BMP pathway signaling.